

About Spherix Global Insights

Spherix is the world's leading Life Sciences market intelligence and advisory services firm, providing unrivaled knowledge and the most informed, actionable insights.

We bring human intelligence to market intelligence. Spherix empowers customers to access critical insights that drive successful decision-making through deep, expert knowledge.

Spherix Provides Independent Expertise in Six Areas



Dermatology



Nephrology



Gastroenterology



Neurology



Rheumatology



Ophthalmology

This is a guide to the publications Spherix will produce in 2024. It is organized by therapeutic area, indication, and deliverable.

Going Beyond the Data

The report is only the beginning. Spherix brings curation and interpretation to market intelligence, working closely with customers to reveal actionable insights that transform markets.

| Type of Publications | | |
|--------------------------|--|--|
| MARKET DYNAMI/ | A yearly market overview of an indication, Market Dynamix provides insights into current treatment paradigms and unmet patient needs as well as physician opinions on how they will likely prescribe new products upon approval. | |
| REALTIME DYNAMIX | A US quarterly or EU5 semi-annual update on an indication, RealTime Dynamix provides trending content on brand use, future intentions, promotional activity, disease awareness and controversy, and pipeline product perceptions. | |
| LAUNCH DYNAMI/ | Published monthly, Launch Dynamix tracks a new brand's first eighteen months of commercial availability. Each quarter includes a deep dive into promotional activity, barriers to uptake, and patient types gravitating to the launch brand. | |
| PATIENT CHART DYNAMIX | A yearly large-scale patient chart audit on an indication, Patient Chart Dynamix unmasks real patient management patterns an uncovers the "why" behind treatment decisions. | |
| SPECIAL TOPIX | Whether the focus is breaking industry news, ongoing trends, conference coverage, or quick-pulse reactions, Special Topix assesses the impact of events in our specialty markets. | |

For a complete index of available reports, visit www.clientportal.spherixglobalinsights.com



2024 Dermatology Publications



| Atopic Dermatitis | | |
|--------------------------|--|--|
| REALTIME DYNAMI/ | Atopic Dermatitis, USAtopic Dermatitis, EU5 | |
| LAUNCH DYNAMIX | Lebrikizumab (Eli Lilly) in Atopic Dermatitis, US* Nemolizumab (Galderma) in Atopic Dermatitis, US* | |
| PATIENT CHART DYNAMI/ | Atopic Dermatitis, USAtopic Dermatitis, EU5 | |
| SPECIAL TOPIX | Atopic Dermatitis - APP (US) Topical Small Molecules in Atopic Dermatitis, US | |

| Plaque Psoriasis | | |
|--------------------------|---|--|
| REALTIME DYNAMI/ | Plaque Psoriasis, USPlaque Psoriasis, EU5 | |
| LAUNCH DYNAMIX | Bimzelx (UCB) in Plaque Psoriasis, US Sotyktu (BMS) in Plaque Psoriasis, US Vtama (Dermavant) in Plaque Psoriasis, US Zoryve (Arcutis) in Plaque Psoriasis, US | |
| PATIENT CHART DYNAMI/ | New Starts + Switching in Plaque Psoriasis, US | |
| SPECIAL TOPIX | Pre-biologics in Plaque Psoriasis, US | |

| Alopecia Areata | | |
|-------------------|--|--|
| MARKET DYNAMI/ | Alopecia Areata, US | |
| LAUNCH DYNAMIX | Deuruxolitinib (SUN Pharma) in Alopecia Areata, US* Litfulo (Pfizer) in Alopecia Areata, US | |

| Hidradenitis Suppurativa | | |
|--------------------------|--|--|
| MARKET DYNAMI/ | Hidradenitis Suppurativa, US | |
| REALTIME DYNAMIX | Hidradenitis Suppurativa, EU5 | |
| LAUNCH DYNAMI/ | Bimzelx (UCB) in Hidradenitis Suppurativa, US Cosentyx (Novartis) in Hidradenitis Suppurativa, US | |
| PATIENT CHART DYNAMIX | Hidradenitis Suppurativa, US | |

| | Other Dermatology | |
|-------------------|---|--|
| MARKET DYNAMI/ | Prurigo Nodularis, USVitiligo, US | |
| LAUNCH DYNAMIX | Dupixent (Sanofi/Regeneron) in Prurigo Nodularis, US Nemolizumab (Galderma) in Prurigo Nodularis, US* Opzelura (Incyte) in Vitiligo, US | |
| SPECIAL TOPI/ | Biologic Coordinators Across Dermatology, US | |

| | MARKET DYNAMIX | Yearly market overview of key indication |
|----------|-----------------------|--|
| | REALTIME DYNAMIX | Quarterly (US) or semi-annual (EU5) indication updates |
| a | LAUNCH DYNAMIX | Monthly benchmark of newly launched products |
| <u> </u> | PATIENT CHART DYNAMIX | Yearly review of large-scale patient chart audits |
| | SPECIAL TOPIX | Current events on specific interest areas |



2024 Gastroenterology Publications



| Inflammatory Bowel Disease | | |
|----------------------------|--|--|
| REALTIME DYNAMI/ | Crohn's Disease, US Crohn's Disease, EU5 Ulcerative Colitis, US Ulcerative Colitis, EU5 | |
| LAUNCH DYNAMIX | Rinvoq (Abbvie) in Crohn's Disease, US Skyrizi (Abbvie) in Crohn's Disease, US Omvoh (Eli Lilly) in Ulcerative Colitis, US Skyrizi (Abbvie) in Ulcerative Colitis, US Velsipity (Pfizer) in Ulcerative Colitis, US | |
| PATIENT CHART DYNAMI/ | Inflammatory Bowel Disease New Starts, US Inflammatory Bowel Disease Switching, US Inflammatory Bowel Disease New Starts, EU | |

| Metabolic Dysfunction-associated Steatotic Liver Disease / Metabolic Dysfunction-associated Steatohepatitis | | |
|---|--------------------------------------|--|
| MARKET DYNAMI/ | • MASLD/MASH, US | |
| LAUNCH DYNAMIX | Resmetirom (Madrigal) in MASLD/MASH* | |
| PATIENT CHART DYNAMI/ | • MASLD/MASH, US | |

| General Gastroenterology | | |
|--------------------------|---|--|
| MARKET DYNAMI/ | Irritable Bowel Syndrome - Constipation, US | |
| LAUNCH DYNAMIX | Rebyota (Ferring) and Vowst (Seres) in Clostridium Difficile Infection, US | |

| Eosinophilic Esophagitis | | |
|--------------------------|--|--|
| MARKET DYNAMI/ | Eosinophilic Esophagitis, US | |
| LAUNCH DYNAMIX | Eohilia (Takeda) in Eosinophilic Esophagitis | |
| PATIENT CHART DYNAMI/ | Eosinophilic Esophagitis, US | |

| | MARKET DYNAMIX | Yearly market overview of key indication |
|-------------|-----------------------|--|
| > | REALTIME DYNAMIX | Quarterly (US) or semi-annual (EU5) indication updates |
| נ | LAUNCH DYNAMIX | Monthly benchmark of newly launched products |
| 1 | PATIENT CHART DYNAMIX | Yearly review of large-scale patient chart audits |
| | SPECIAL TOPIX | Current events on specific interest areas |



2024 Rheumatology Publications



Ankylosing Spondylitis & Non-Radiographic Axial Spondyloarthritis

| REALTIME DYNAMI/ | Ankylosing Spondylitis & Non-Radiographic Axial Spondyloarthritis, US Ankylosing Spondylitis & Non-Radiographic Axial Spondyloarthritis, EU5 |
|---------------------|---|
| LAUNCH | Bimzelx (UCB) in Ankylosing Spondylitis & Non- |
| DYNAMIX | Radiographic Axial Spondyloarthritis, US* |

| Psoriatic Arthritis | | |
|--------------------------|--|--|
| REALTIME DYNAMI/ | Psoriatic Arthritis, US Psoriatic Arthritis, EU5 | |
| LAUNCH DYNAMIX | Bimzelx (UCB) in Psoriatic Arthritis, US | |
| PATIENT CHART DYNAMI/ | Triggers and Drivers in Psoriatic Arthritis Switching, US | |

| Lupus | | |
|--------------------------|--|--|
| REALTIME DYNAMI/ | Lupus Nephritis, US Systemic Lupus Erythematosus, US Systemic Lupus Erythematosus, EU5 | |
| PATIENT CHART DYNAMIX | Lupus Nephritis, USSystemic Lupus Erythematosus, USSystemic Lupus Erythematosus, EU5 | |

| | General Rheumatology |
|-------------------------------|---|
| MARKET DYNAMI/ REALTIME | Dermatomyositis, US Giant Cell Arteritis, US Polymyalgia Rheumatica, US Systemic Sclerosis, US Systemic Sclerosis, EU |
| DYNAMIX LAUNCH | Rheumatoid Arthritis, US |
| DYNAMIX | Kevzara (Sanofi/Regeneron) in Polymyalgia Rheumatica, US |
| SPECIAL TOPIX | American College of Rheumatology (ACR) Convergence Feedback, US |

| , | MARKET DYNAMIX | Yearly market overview of key indication |
|-----|-----------------------|--|
| | REALTIME DYNAMIX | Quarterly (US) or semi-annual (EU5) indication updates |
| Key | LAUNCH DYNAMIX | Monthly benchmark of newly launched products |
| _ | PATIENT CHART DYNAMIX | Yearly review of large-scale patient chart audits |
| | SPECIAL TOPIX | Current events on specific interest areas |

2024 Nephrology Publications



| Kidney Disease | | |
|--------------------------|---|--|
| MARKET DYNAMI/ | Autosomal Dominant Polycystic Kidney Disease, US Chronic Kidney Disease - Cardiorenal, US End-Stage Kidney Disease Modalities (Dialysis and Transplant), US | |
| REALTIME DYNAMIX | Chronic Kidney Disease/Diabetic Kidney Disease, US Dialysis, US | |
| PATIENT CHART DYNAMI/ | Chronic Kidney Disease, Non-Dialysis, US Chronic Kidney Disease, Non-Dialysis, PCP, US Dialysis, US | |
| SPECIAL TOPIX | ASN Kidney Week Conference, USBuy and Bill in Nephrology Practices | |

| Glomerular Diseases | | |
|--------------------------|--|--|
| MARKET DYNAMI/ | Complement Disorders, US Focal Segmental Glomerulosclerosis, US Membranous Nephropathy, US Rare Glomerular Diseases, Japan Rare Glomerular Diseases, EU5 | |
| REALTIME DYNAMI/ | • IgA Nephropathy, US | |
| LAUNCH DYNAMI/ | Filspari (Travere) in IgA Nephropathy, US | |
| PATIENT CHART DYNAMIX | Complement 3 Glomerulopathy, EU5 IgA Nephropathy, US IgA Nephropathy, EU5 | |

| Bone and Mineral Metabolism | |
|-----------------------------|--|
| LAUNCH | Xphozah (Ardelyx) in Hyperphosphatemia, US Xphozah (Ardelyx) in Hyperphosphatemia, Renal |
| DYNAMI/ | Dietitians, US |

| | Lupus |
|--------------------------|-----------------------|
| REALTIME DYNAMI/ | • Lupus Nephritis, US |
| PATIENT CHART DYNAMIX | • Lupus Nephritis, US |

| Renal Anemia | |
|---------------------|---|
| REALTIME DYNAMI/ | Renal Anemia, EU5 |
| LAUNCH DYNAMIX | Jesduvroq (GSK) in Renal Anemia, USVadadustat (Akebia) in Renal Anemia, US |

| MARKET DYNAMIX | Yearly market overview of key indication |
|-----------------------|--|
| REALTIME DYNAMIX | Quarterly (US) or semi-annual (EU5) indication updates |
| LAUNCH DYNAMIX | Monthly benchmark of newly launched products |
| PATIENT CHART DYNAMIX | Yearly review of large-scale patient chart audits |
| SPECIAL TOPIX | Current events on specific interest areas |



2024 Neurology Publications



| Generalized Myasthenia Gravis | | |
|-------------------------------|---|--|
| MARKET DYNAMI/ | Generalized Myasthenia Gravis, US | |
| REALTIME DYNAMI/ | Generalized Myasthenia Gravis, EU5 | |
| LAUNCH DYNAMI/ | SC Vyvgart Hytrulo (Argenx), Rystiggo (UCB) and Zilucoplan (UCB) in Generalized Myasthenia Gravis, US | |
| PATIENT CHART DYNAMIX | General Myasthenia Gravis, US | |

| | Migraine |
|---------------------|---|
| REALTIME DYNAMI/ | Migraine, US |
| LAUNCH DYNAMIX | Zavzpret (Pfizer) in Acute Migraine, US |

| | Alzheimer's Disease |
|--------------------------|---|
| MARKET DYNAMI/ | Alzheimer's Disease, US |
| REALTIME DYNAMIX | Alzheimer's Disease, EU5 |
| LAUNCH DYNAMI/ | Donanemab (Lilly) in Alzheimer's Disease, US* Leqembi (Eisai/Biogen)in Alzheimer's Disease, US |
| PATIENT CHART DYNAMIX | Alzheimer's Disease, US |
| SPECIAL TOPI, | Alzheimer's Disease Modifying Therapies vs. Symptomatics, US |

| Multiple Sclerosis | | |
|---------------------|---|--|
| REALTIME DYNAMI/ | Multiple Sclerosis, US | |
| LAUNCH DYNAMIX | SC Ocrelizumab (Genentech) in Multiple Sclerosis* | |

General Neurology & Neurodegeneration

| MARKET | Amyotrophic Lateral Sclerosis, US Chronic Inflammatory Demyelinating |
|------------------|--|
| DYNAMI/ | Polyneuropathy, US Epilepsy, US Huntington's Disease, US Parkinson's Disease, US Post-Acute Stroke, US |
| SPECIAL TOPIX | Evolving Therapies in Parkinson's Disease, US |

| | MARKET DYNAMIX | Yearly market overview of key indication |
|----------|-----------------------|--|
| | REALTIME DYNAMIX | Quarterly (US) or semi-annual (EU5) indication updates |
| (e) | LAUNCH DYNAMIX | Monthly benchmark of newly launched products |
| <u>~</u> | PATIENT CHART DYNAMIX | Yearly review of large-scale patient chart audits |
| | SPECIAL TOPIX | Current events on specific interest areas |



2024 Ophthalmology Publications



| Neovascular Age-Related Macular Degeneration | |
|---|--|
| REALTIME DYNAMI/ | Neovascular Age-Related Macular Degeneration, US Neovascular Age-Related Macular Degeneration, EU5 |
| LAUNCH DYNAMIX | Eylea HD (Regeneron/Bayer) in Neovascular Age- Related Macular Degeneration and Diabetic Macular Edema, US |
| PATIENT CHART DYNAMI/ | Neovascular Age-Related Macular Degeneration - Switching, US |

| Other Ophthalmology | |
|---------------------|---|
| MARKET DYNAMI/ | Diabetic Retinopathy, USGeographic Atrophy, US |
| LAUNCH DYNAMIX | Syfovre (Apellis) and Izervay (Iveric Bio) in Geographic Atrophy, US |
| SPECIAL TOPI/ | Gene Therapies in Retina, US |

| Diabetic Macular Edema | | |
|--------------------------|--|--|
| REALTIME DYNAMI/ | Diabetic Macular Edema, US | |
| LAUNCH DYNAMI/ | • Eylea HD (Regeneron/Bayer) in Neovascular Age- Related Macular Degeneration and Diabetic Macular Edema, US | |
| PATIENT CHART DYNAMI/ | Diabetic Macular Edema, US | |



Visit The Spherix Portal



